Skip to main content

SCYNEXIS to Participate in Maxim Group’s Late Stage Innovations in Women’s Health Virtual Event

Written by Customer Service on . Posted in Public Companies.

JERSEY CITY, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, President and Chief Executive Officer, will participate in a panel discussion during Maxim Group LLC’s Late Stage Innovations in Women’s Health event, which is part of the M-Vest Virtual Conference series. The virtual event will take place at 11:00 am Eastern Time on March 4, 2021.
The panel will be moderated by Jason McCarthy, PhD, Senior Managing Director and Head of Biotechnology Research – Equity Research at Maxim Group.During the panel discussion, Dr. Taglietti will share insight on Brexafemme, an oral antifungal product candidate under review by the U.S. Food and Drug Administration (FDA) for the treatment of vaginal yeast infection, also known as vulvovaginal candidiasis (VVC), with a Prescription Drug User Fee Act (PDUFA) action date of June 1, 2021.For additional information on the event and to register, please click here.About SCYNEXISCONTACT: 
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.comMedia Relations
Gloria Gasaatura
LifeSci Communications
Tel: (646) 970-4688
ggasaatura@lifescicomms.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.